Skip to main content

Table 2 Initial treatment regimens of 90 anti-MDA5 positive patients

From: Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients

Variables (n = 90)

Value

Initial combination therapy, n (%)

58 (64.4)

High dose GC + CNI, n (%)

30 (30.0)

High dose GC + CYC, n (%)

21 (23.3)

High dose GC + CNI + CYC, n (%)

7 (7.8)

Step-up therapy, n (%)

32 (35.6%)

Additional treatment

 

IVIG, n (%)

43 (47.8)

Hemodialysis

2 (2.22)

  1. anti-MDA5, anti-melanoma differentiation-associated protein-5; GC, glucocorticoid; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172